Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 26
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1251 | SITA INFORMATION NETWORKING COMPUTING UK | 12 | 216.7% | 0 | 10 | 2022–2025 |
| 1252 | SK TELECOM | 12 | 650% | 0 | 6 | 2020–2023 |
| 1253 | SMC | 12 | 433.3% | 0 | 8 | 2021–2026 |
| 1254 | SPINNOVA | 12 | 00% | 0 | 12 | 2024–2025 |
| 1255 | STARLINGER GESELLSCHAFT M B H | 12 | 18.3% | 0 | 11 | 2015–2025 |
| 1256 | STEPAN | 12 | 00% | 0 | 12 | 2022–2026 |
| 1257 | STUDIENGESELLSCHAFT KOHLE GGMBH | 12 | 00% | 0 | 12 | 2023–2026 |
| 1258 | SUN PATENT TRUST | 12 | 866.7% | 0 | 4 | 2022–2024 |
| 1259 | SYNTHEKINE | 12 | 00% | 3 | 9 | 2022–2025 |
| 1260 | TAKEMOTO OIL FAT | 12 | 00% | 0 | 12 | 2024–2026 |
| 1261 | TECNORED DESENVOLVIMENTO TECNOLOGICO | 12 | 00% | 0 | 12 | 2023–2025 |
| 1262 | TEIJIN PHARMA | 12 | 216.7% | 1 | 9 | 2019–2026 |
| 1263 | TOYODA GOSEI | 12 | 00% | 0 | 12 | 2025–2025 |
| 1264 | UNILIN | 12 | 216.7% | 0 | 10 | 2021–2026 |
| 1265 | VALENT BIOSCIENCES | 12 | 18.3% | 0 | 11 | 2022–2025 |
| 1266 | VALEO JAPAN | 12 | 325% | 1 | 8 | 2020–2024 |
| 1267 | VALMET | 12 | 18.3% | 0 | 11 | 2022–2026 |
| 1268 | VIB VZW | 12 | 00% | 2 | 10 | 2022–2025 |
| 1269 | VITO | 12 | 216.7% | 2 | 8 | 2022–2026 |
| 1270 | WIELAND WERKE | 12 | 00% | 0 | 12 | 2023–2025 |
| 1271 | XENCOR | 12 | 00% | 0 | 12 | 2023–2026 |
| 1272 | XINJIANG GOLDWIND SCIENCE TECHNOLOGY | 12 | 1083.3% | 0 | 2 | 2022–2022 |
| 1273 | YAMATO SCALE | 12 | 650% | 0 | 6 | 2022–2025 |
| 1274 | ZUIKO | 12 | 18.3% | 0 | 11 | 2022–2026 |
| 1275 | 3D SYSTEMS | 11 | 654.5% | 0 | 5 | 2022–2026 |
| 1276 | ABBISKO THERAPEUTICS | 11 | 19.1% | 0 | 10 | 2022–2026 |
| 1277 | ADD ADVANCED DRUG DELIVERY TECHNOLOGIES | 11 | 218.2% | 0 | 9 | 2021–2025 |
| 1278 | AISAN KOGYO | 11 | 19.1% | 4 | 6 | 2022–2026 |
| 1279 | ALD VACUUM TECHNOLOGIES | 11 | 19.1% | 0 | 10 | 2022–2026 |
| 1280 | AMICUS THERAPEUTICS | 11 | 00% | 1 | 10 | 2022–2025 |
| 1281 | ARGO | 11 | 00% | 1 | 10 | 2023–2025 |
| 1282 | ARIEL SCIENTIFIC INNOVATIONS | 11 | 19.1% | 2 | 8 | 2021–2026 |
| 1283 | ASAHI DENSO | 11 | 00% | 0 | 11 | 2022–2026 |
| 1284 | BEONE MEDICINES I | 11 | 00% | 0 | 11 | 2025–2026 |
| 1285 | BIOCONSORTIA | 11 | 00% | 0 | 11 | 2023–2026 |
| 1286 | BYK CHEMIE | 11 | 218.2% | 0 | 9 | 2023–2026 |
| 1287 | CABOT | 11 | 00% | 0 | 11 | 2022–2026 |
| 1288 | CELANESE INTERNATIONAL | 11 | 00% | 2 | 9 | 2022–2026 |
| 1289 | CHASM ADVANCED MATERIALS | 11 | 19.1% | 0 | 10 | 2023–2026 |
| 1290 | CHEP TECHNOLOGY PTY | 11 | 19.1% | 0 | 10 | 2021–2024 |
| 1291 | CRINETICS PHARMACEUTICALS | 11 | 218.2% | 1 | 8 | 2022–2026 |
| 1292 | CRYOSHELTER LH2 | 11 | 00% | 0 | 11 | 2023–2026 |
| 1293 | CTC GLOBAL | 11 | 00% | 0 | 11 | 2022–2025 |
| 1294 | CUBICPV | 11 | 19.1% | 6 | 4 | 2022–2024 |
| 1295 | D AUS ENERGY STORAGE TECHNOLOGY XI AN | 11 | 00% | 0 | 11 | 2024–2026 |
| 1296 | DEBIOPHARM INTERNATIONAL | 11 | 19.1% | 3 | 7 | 2022–2026 |
| 1297 | DOUYIN VISION | 11 | 00% | 0 | 11 | 2024–2025 |
| 1298 | DOWA METALTECH | 11 | 00% | 0 | 11 | 2023–2025 |
| 1299 | DRYAD NETWORKS | 11 | 00% | 3 | 8 | 2022–2024 |
| 1300 | EAVOR TECHNOLOGIES | 11 | 19.1% | 3 | 7 | 2022–2026 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →